EUVIMEDEUVIMED entdecken
Crossref

A Galactose‐Engineered Dual‐Responsive Nanocarrier for ASO/CRISPR‐Cas9 Delivery to Inhibit HBV Replication

Liuxian Chen, Qin Huang, Yongjie Liu, Ke Chen, Qing Yang, Hua Tang, Dan Wang, Zhenrong Tang iD

Advanced Healthcare Materials · 2026

DOI: 10.1002/adhm.202502835 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2026. Verfasst von Liuxian Chen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Chongqing Medical University, No. 1, Yixueyuan Road, Chongqing, …. Hauptthemen laut MEDLINE: Hepatitis B virus, CRISPR-Cas Systems, Virus Replication, Oligonucleotides, Antisense. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 84 Literaturangaben. Gefördert von: China Postdoctoral Science Foundation, Chongqing Medical University Top Talent Cultivation Program, Natural Science Foundation of Chongqing.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Complete hepatitis B virus (HBV) cure is hindered primarily by the stable persistence of covalently closed circular DNA (cccDNA). Gene editing approaches to eradicate HBV by targeting cccDNA face challenges and limitations due to suboptimal editing efficiency and substantial off‐target effects. Herein, a combinatorial therapeutic strategy is developed that integrates CRISPR/Cas9‐mediated cccDNA disruption with an antisense oligonucleotide (ASO)‐targeted degradation of pregenomic RNA (pgRNA). To overcome delivery challenges, a hepatocyte‐targeting nanocarrier (UACPG) is engineered, featuring low immunogenicity, high payload capacity, and dual‐stimuli responsiveness. The UACPG platform enabled liver‐specific delivery through surface‐conjugated targeting ligands, followed by on‐demand release of Cas9 ribonucleoprotein complexes and ASO via RNase H‐dependent degradation and near‐infrared (NIR) light activation. The results demonstrated that UACPG can effectively reduce HBV replication and viral antigen levels, while significantly lowering cccDNA in hydrodynamic HBV‐infected mouse models, with no significant off‐target effects observed. This nanocarrier achieved the spatiotemporally controlled release of gene‐editing systems in vitro and in vivo, significantly inhibiting the replication of HBV, thereby establishing an innovative technological platform for developing curative HBV therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis B virusCRISPR-Cas SystemsVirus ReplicationOligonucleotides, AntisenseGalactoseNanoparticlesDrug CarriersAnimalsHumansMiceHepatitis BGene EditingHep G2 Cells

Stichwörter der Autor:innen

ASOCRISPR/Cas9HBVliver‐targetingnanoparticle delivery

Substanzen

Oligonucleotides, AntisenseGalactoseDrug Carriers

Autor:innen und Institutionen

  • Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Chongqing Medical University, No. 1, Yixueyuan Road, Chongqing, 400016, China.
  • Bishan Hospital of Chongqing Medical University, Bishan Hospital of Chongqing, No. 9, Shuangxing Avenue, Chong qing, 402760, China.
  • Post-Doctoral Research Center, The People's Hospital of Rongchang District, No. 3, Guangchang North Road, Chongqing, 402400, China.
  • Yunyang Hospital, Chonqqing University of Chinese Medicine, No. 618, Beicheng Avenue, Chong qing, 404500, China.
  • Department of Breast and Thyroid Surgery, Chongqing Key Laboratory of Molecular Oncology and Epigenetics, The First Affiliated Hospital of Chongqing Medical University, No.1, youyi Road, Chongqing, 400016, China.

ORCID-Profile: Zhenrong Tang

Förderung

  • China Postdoctoral Science Foundation
  • Chongqing Medical University Top Talent Cultivation Program
  • Natural Science Foundation of Chongqing
  • Chongqing Municipal Key Research and Development Program of China
  • Natural Science Foundation of Chongqing Municipality

Zitieren

APA

Chen, L., Huang, Q., Liu, Y., Chen, K., Yang, Q., Tang, H., Wang, D., & Tang, Z. (2026). A Galactose‐Engineered Dual‐Responsive Nanocarrier for ASO/CRISPR‐Cas9 Delivery to Inhibit HBV Replication. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202502835

Vancouver

Chen L, Huang Q, Liu Y, Chen K, Yang Q, Tang H, et al. A Galactose‐Engineered Dual‐Responsive Nanocarrier for ASO/CRISPR‐Cas9 Delivery to Inhibit HBV Replication. Advanced Healthcare Materials. 2026. doi:10.1002/adhm.202502835

BibTeX
@article{Chen2026,
  author = {Chen, Liuxian and Huang, Qin and Liu, Yongjie and Chen, Ke and Yang, Qing and Tang, Hua and Wang, Dan and Tang, Zhenrong},
  title = {A Galactose‐Engineered Dual‐Responsive Nanocarrier for ASO/CRISPR‐Cas9 Delivery to Inhibit HBV Replication},
  journal = {Advanced Healthcare Materials},
  year = {2026},
  doi = {10.1002/adhm.202502835}
}
Kostenlos starten →